TCR Discovery & Validation
Claudia Wagner joined Immatics in May 2012 and is responsible for T-cell receptor (TCR) discovery and validation on the XCEPTOR™ platform. In her department, TCRs recognizing proprietary XPRESIDENT® tumor antigens are isolated from blood products of healthy individuals and patients, followed-by extensive characterization in human cells. Suitable candidates for immunotherapy, either for adoptive cell therapy (ACT) or soluble TCR bispecifics, are tested preclinically for efficacy and safety. Additionally, Claudia is responsible for the refolding unit of peptide-MHC complexes at Immatics.
In 2006, Claudia Wagner obtained her immunology-focused PhD at the Center for Infectious Medicine at Karolinska Institutet, Stockholm, Sweden. She was then trained as postdoctoral fellow in the Department of Immunobiology at Yale University, New Haven, USA prior to joining Immatics. Claudia also holds a master’s degree in Biomedicine from the Karolinska Institutet.